Impact of Non‐Alcoholic Fatty Liver Disease on the HBsAg Loss of Patients With Chronic Hepatitis B Treated in Pegylated Interferon Alpha

医学 乙型肝炎表面抗原 内科学 胃肠病学 聚乙二醇干扰素 脂肪肝 乙型肝炎 回顾性队列研究 肝病 人口 慢性肝炎 非酒精性脂肪肝 减肥 队列 肝病学 队列研究 联合疗法 倾向得分匹配 慢性肝病 丙型肝炎 乙型肝炎病毒 前瞻性队列研究 人口研究 疾病 α-干扰素 免疫学
作者
Chujing Li,Lihua Lin,Pei Zhou,Haiyi Cai,Songlian Liu,Xiaoyuan Chen,Aiqi Lu,Bo Li,Yaping Wang,Chuanghua Luo,Jianping Li,Yujuan Guan,Zhiwei Xie
出处
期刊:Journal of Viral Hepatitis [Wiley]
卷期号:33 (1): e70115-e70115 被引量:4
标识
DOI:10.1111/jvh.70115
摘要

Whether combining non-alcoholic fatty liver disease (NAFLD) affects the efficacy of pegylated interferon alpha (PEG-IFN-α) for patients with chronic hepatitis B (CHB) remains unknown; hence, we aimed to conduct a retrospective cohort study to investigate the impact of NAFLD on the HBsAg loss rate of CHB treated with PEG-IFN-α. A total of 279 adult CHB patients receiving antiviral therapy with PEG-IFN-α were included in the study, of which 94 (33.7%) patients had combined NAFLD. The median treatment duration in the overall population was 37 (23, 59) weeks, and 79 (28.3%) patients achieved serum HBsAg loss during treatment. Compared to patients without NAFLD, patients with NAFLD had lower baseline HBsAg levels prior to treatment with PEG-IFN-α (438.05 [152.77, 978.60] vs. 296.60 [54.20, 647.15] IU/mL, p = 0.004). Propensity score matching (PSM) was applied to rectify the baseline characteristics between the two groups, including age, gender and quantitative HBsAg level. After PSM, 84 CHB with NAFLD and 84 CHB without NAFLD were included in the matched cohort. With a comparable treatment duration in both groups, the patients with NAFLD had a lower cumulative HBsAg loss rate (Log-rank p = 0.007). Multivariable analysis suggested that NAFLD was independently associated with a decrease in HBsAg loss rates (risk ratio HR = 0.505; 95% CI, 0.283-0.902; p = 0.021), which was consistent in sensitivity analyses that included only nucleos(t)ide analogue (NA)-treated patients. In conclusion, CHB with NAFLD demonstrated a lower HBsAg loss rate during PEG-IFN-α treatment, suggesting that more optimal therapeutic strategies need to be further explored.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
ymorningrock发布了新的文献求助10
刚刚
刚刚
刚刚
SciGPT的应助被科研通管家采纳,获得10
刚刚
大聪明发布了新的文献求助10
1秒前
1秒前
1秒前
1秒前
1秒前
钟梓袄发布了新的文献求助10
2秒前
互助完成签到,获得积分0
2秒前
自信诗桃发布了新的文献求助10
2秒前
欣q完成签到 ,获得积分10
2秒前
2秒前
yi发布了新的文献求助10
2秒前
RUI发布了新的文献求助10
2秒前
orixero的应助被Miraitowa采纳,获得10
3秒前
3秒前
qin202569发布了新的文献求助10
3秒前
lyb发布了新的文献求助10
3秒前
4秒前
wanci的应助被哎哟可爱采纳,获得10
4秒前
4秒前
老实灵安完成签到,获得积分10
5秒前
温暖砖头发布了新的文献求助10
5秒前
英勇冰淇淋完成签到 ,获得积分10
5秒前
迷路的灵波的应助被SKHC采纳,获得10
5秒前
遇事不慌张女士完成签到,获得积分20
6秒前
6秒前
慕青的应助被1097采纳,获得10
6秒前
可爱的函函的应助被无敌啊豹采纳,获得10
7秒前
追寻的梦岚完成签到,获得积分20
7秒前
何曼慈发布了新的文献求助10
8秒前
8秒前
8秒前
俭朴的雁开完成签到,获得积分10
9秒前
王俊完成签到,获得积分10
9秒前
vicky完成签到,获得积分10
9秒前
9秒前
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183142
求助须知:如何正确求助?哪些是违规求助? 9572420
关于积分的说明 21825253
捐赠科研通 7779922
什么是DOI,文献DOI怎么找? 3433850
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480124